Annual Cash & Cash Equivalents
$6.90 B
-$2.99 B-30.22%
31 December 2023
Summary:
Abbott Laboratories annual cash & cash equivalents is currently $6.90 billion, with the most recent change of -$2.99 billion (-30.22%) on 31 December 2023. During the last 3 years, it has risen by +$58.00 million (+0.85%). ABT annual cash & cash equivalents is now -62.96% below its all-time high of $18.62 billion, reached on 31 December 2016.ABT Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Cash And Cash Equivalents
$7.56 B
+$571.00 M+8.17%
30 September 2024
Summary:
Abbott Laboratories quarterly cash and cash equivalents is currently $7.56 billion, with the most recent change of +$571.00 million (+8.17%) on 30 September 2024. Over the past year, it has increased by +$849.00 million (+12.65%). ABT quarterly cash and cash equivalents is now -59.41% below its all-time high of $18.62 billion, reached on 31 December 2016.ABT Quarterly Cash And Cash Equivalents Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ABT Cash And Cash Equivalents Performance
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
---|---|---|
1 y1 year | -30.2% | +12.7% |
3 y3 years | +0.8% | -18.8% |
5 y5 years | +79.4% | +84.8% |
ABT Cash And Cash Equivalents High & Low
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
---|---|---|---|---|---|
3 y | 3 years | -30.2% | +0.8% | -23.5% | +20.3% |
5 y | 5 years | -30.2% | +79.4% | -23.5% | +123.8% |
alltime | all time | -63.0% | >+9999.0% | -59.4% | >+9999.0% |
Abbott Laboratories Cash And Cash Equivalents History
Date | Annual | Quarterly |
---|---|---|
Sept 2024 | - | $7.56 B(+8.2%) |
June 2024 | - | $6.99 B(+11.2%) |
Mar 2024 | - | $6.28 B(-8.9%) |
Dec 2023 | $6.90 B(-30.2%) | $6.90 B(+2.8%) |
Sept 2023 | - | $6.71 B(-14.4%) |
June 2023 | - | $7.83 B(-14.5%) |
Mar 2023 | - | $9.16 B(-7.3%) |
Dec 2022 | $9.88 B(+0.8%) | $9.88 B(+3.0%) |
Sept 2022 | - | $9.59 B(+7.4%) |
June 2022 | - | $8.94 B(+16.4%) |
Mar 2022 | - | $7.67 B(-21.7%) |
Dec 2021 | $9.80 B(+43.3%) | $9.80 B(+5.3%) |
Sept 2021 | - | $9.30 B(+7.4%) |
June 2021 | - | $8.66 B(+7.5%) |
Mar 2021 | - | $8.05 B(+17.8%) |
Dec 2020 | $6.84 B(+77.2%) | $6.84 B(+52.6%) |
Sept 2020 | - | $4.48 B(-5.9%) |
June 2020 | - | $4.76 B(+41.0%) |
Mar 2020 | - | $3.38 B(-12.5%) |
Dec 2019 | $3.86 B(+0.4%) | $3.86 B(-5.6%) |
Sept 2019 | - | $4.09 B(+30.4%) |
June 2019 | - | $3.14 B(+3.8%) |
Mar 2019 | - | $3.02 B(-21.4%) |
Dec 2018 | $3.84 B(-59.1%) | $3.84 B(-47.8%) |
Sept 2018 | - | $7.37 B(+140.4%) |
June 2018 | - | $3.06 B(-20.5%) |
Mar 2018 | - | $3.86 B(-59.0%) |
Dec 2017 | $9.41 B(-49.5%) | $9.41 B(-14.6%) |
Sept 2017 | - | $11.01 B(+13.8%) |
June 2017 | - | $9.68 B(+11.1%) |
Mar 2017 | - | $8.71 B(-53.2%) |
Dec 2016 | $18.62 B(+272.3%) | $18.62 B(+644.8%) |
Sept 2016 | - | $2.50 B(-3.0%) |
June 2016 | - | $2.58 B(-22.7%) |
Mar 2016 | - | $3.33 B(-33.3%) |
Dec 2015 | $5.00 B(+23.1%) | $5.00 B(+59.7%) |
Sept 2015 | - | $3.13 B(-22.6%) |
June 2015 | - | $4.05 B(+25.5%) |
Mar 2015 | - | $3.23 B(-20.6%) |
Dec 2014 | $4.06 B(+16.9%) | $4.06 B(+12.5%) |
Sept 2014 | - | $3.61 B(+1.2%) |
June 2014 | - | $3.57 B(+73.3%) |
Mar 2014 | - | $2.06 B(-40.7%) |
Dec 2013 | $3.48 B(-67.8%) | $3.48 B(+20.6%) |
Sept 2013 | - | $2.88 B(-48.3%) |
June 2013 | - | $5.57 B(+27.4%) |
Mar 2013 | - | $4.37 B(-59.5%) |
Dec 2012 | $10.80 B(+58.6%) | $10.80 B(+35.1%) |
Sept 2012 | - | $8.00 B(+13.4%) |
June 2012 | - | $7.05 B(+62.3%) |
Mar 2012 | - | $4.35 B(-36.2%) |
Dec 2011 | $6.81 B(+86.7%) | $6.81 B(+34.9%) |
Sept 2011 | - | $5.05 B(+23.8%) |
June 2011 | - | $4.08 B(+48.8%) |
Mar 2011 | - | $2.74 B(-24.9%) |
Dec 2010 | $3.65 B(-58.6%) | $3.65 B(-4.4%) |
Sept 2010 | - | $3.82 B(-11.7%) |
June 2010 | - | $4.32 B(+175.8%) |
Mar 2010 | - | $1.57 B(-82.2%) |
Dec 2009 | $8.81 B(+114.2%) | $8.81 B(+80.7%) |
Sept 2009 | - | $4.88 B(+16.0%) |
June 2009 | - | $4.20 B(-13.8%) |
Mar 2009 | - | $4.87 B(+18.5%) |
Dec 2008 | $4.11 B(+67.4%) | $4.11 B(+46.3%) |
Sept 2008 | - | $2.81 B(-26.0%) |
June 2008 | - | $3.80 B(+40.1%) |
Mar 2008 | - | $2.71 B(+10.3%) |
Dec 2007 | $2.46 B(+371.3%) | $2.46 B(+28.6%) |
Sept 2007 | - | $1.91 B(+24.2%) |
June 2007 | - | $1.54 B(+125.5%) |
Mar 2007 | - | $682.35 M(+30.9%) |
Dec 2006 | $521.19 M | $521.19 M(-1.0%) |
Date | Annual | Quarterly |
---|---|---|
Sept 2006 | - | $526.37 M(-33.4%) |
June 2006 | - | $790.90 M(-66.2%) |
Mar 2006 | - | $2.34 B(-19.0%) |
Dec 2005 | $2.89 B(+136.1%) | $2.89 B(+1.7%) |
Sept 2005 | - | $2.85 B(+96.6%) |
June 2005 | - | $1.45 B(-15.0%) |
Mar 2005 | - | $1.70 B(+39.0%) |
Dec 2004 | $1.23 B(+23.2%) | $1.23 B(+51.1%) |
Sept 2004 | - | $810.89 M(-34.2%) |
June 2004 | - | $1.23 B(+9.6%) |
Mar 2004 | - | $1.12 B(+12.9%) |
Dec 2003 | $995.12 M(+41.3%) | $995.12 M(-40.8%) |
Sept 2003 | - | $1.68 B(+55.9%) |
June 2003 | - | $1.08 B(+5.7%) |
Mar 2003 | - | $1.02 B(+44.9%) |
Dec 2002 | $704.45 M(+7.2%) | $704.45 M(-5.1%) |
Sept 2002 | - | $742.65 M(+54.0%) |
June 2002 | - | $482.14 M(-49.0%) |
Mar 2002 | - | $944.98 M(+43.8%) |
Dec 2001 | $657.38 M(-28.1%) | $657.38 M(+10.6%) |
Sept 2001 | - | $594.15 M(-10.6%) |
June 2001 | - | $664.75 M(+35.1%) |
Mar 2001 | - | $492.19 M(-46.2%) |
Dec 2000 | $914.22 M(+50.3%) | $914.22 M(+4.1%) |
Sept 2000 | - | $878.12 M(+4.5%) |
June 2000 | - | $840.15 M(+23.4%) |
Mar 2000 | - | $680.89 M(+12.0%) |
Dec 1999 | $608.10 M(+92.9%) | $608.10 M(+14.5%) |
Sept 1999 | - | $531.07 M(+53.6%) |
June 1999 | - | $345.78 M(-1.7%) |
Mar 1999 | - | $351.76 M(+11.6%) |
Dec 1998 | $315.20 M(+37.0%) | $315.20 M(+41.0%) |
Sept 1998 | - | $223.47 M(-11.2%) |
June 1998 | - | $251.77 M(+11.6%) |
Mar 1998 | - | $225.54 M(-1.9%) |
Dec 1997 | $230.00 M(+108.7%) | $230.00 M(+77.7%) |
Sept 1997 | - | $129.40 M(+2.3%) |
June 1997 | - | $126.52 M(-5.6%) |
Mar 1997 | - | $134.09 M(+21.7%) |
Dec 1996 | $110.20 M(-60.8%) | $110.20 M(-21.2%) |
Sept 1996 | - | $139.90 M(+25.5%) |
June 1996 | - | $111.48 M(+26.8%) |
Mar 1996 | - | $87.92 M(-68.7%) |
Dec 1995 | $281.20 M(-3.1%) | $281.20 M(-12.3%) |
Sept 1995 | - | $320.80 M(+26.1%) |
June 1995 | - | $254.40 M(+38.1%) |
Mar 1995 | - | $184.21 M(-36.5%) |
Dec 1994 | $290.27 M(-3.5%) | $290.27 M(+30.7%) |
Sept 1994 | - | $222.03 M(+22.9%) |
June 1994 | - | $180.60 M(+5.6%) |
Mar 1994 | - | $171.06 M(-43.1%) |
Dec 1993 | $300.68 M(+157.9%) | $300.68 M(+118.2%) |
Sept 1993 | - | $137.80 M(+367.1%) |
June 1993 | - | $29.50 M(-42.7%) |
Mar 1993 | - | $51.50 M(-55.8%) |
Dec 1992 | $116.60 M(+93.0%) | $116.60 M(+328.7%) |
Sept 1992 | - | $27.20 M(-29.2%) |
June 1992 | - | $38.40 M(+70.7%) |
Mar 1992 | - | $22.50 M(-62.7%) |
Dec 1991 | $60.40 M(+77.6%) | $60.40 M(+22.0%) |
Sept 1991 | - | $49.50 M(-14.2%) |
June 1991 | - | $57.70 M(+6.3%) |
Mar 1991 | - | $54.30 M(+59.7%) |
Dec 1990 | $34.00 M(+150.0%) | $34.00 M(-71.1%) |
Sept 1990 | - | $117.50 M(+225.5%) |
June 1990 | - | $36.10 M(-52.9%) |
Mar 1990 | - | $76.60 M(+463.2%) |
Dec 1989 | $13.60 M(-97.7%) | $13.60 M(-97.7%) |
Dec 1988 | $582.60 M(+12.1%) | $582.60 M(+12.1%) |
Dec 1987 | $519.90 M(+8.0%) | $519.90 M(+8.0%) |
Dec 1986 | $481.60 M(+10.1%) | $481.60 M(+10.1%) |
Dec 1985 | $437.50 M(-2.1%) | $437.50 M(-2.1%) |
Dec 1984 | $447.10 M | $447.10 M |
FAQ
- What is Abbott Laboratories annual cash & cash equivalents?
- What is the all time high annual cash & cash equivalents for Abbott Laboratories?
- What is Abbott Laboratories annual cash & cash equivalents year-on-year change?
- What is Abbott Laboratories quarterly cash and cash equivalents?
- What is the all time high quarterly cash and cash equivalents for Abbott Laboratories?
- What is Abbott Laboratories quarterly cash and cash equivalents year-on-year change?
What is Abbott Laboratories annual cash & cash equivalents?
The current annual cash & cash equivalents of ABT is $6.90 B
What is the all time high annual cash & cash equivalents for Abbott Laboratories?
Abbott Laboratories all-time high annual cash & cash equivalents is $18.62 B
What is Abbott Laboratories annual cash & cash equivalents year-on-year change?
Over the past year, ABT annual cash & cash equivalents has changed by -$2.99 B (-30.22%)
What is Abbott Laboratories quarterly cash and cash equivalents?
The current quarterly cash and cash equivalents of ABT is $7.56 B
What is the all time high quarterly cash and cash equivalents for Abbott Laboratories?
Abbott Laboratories all-time high quarterly cash and cash equivalents is $18.62 B
What is Abbott Laboratories quarterly cash and cash equivalents year-on-year change?
Over the past year, ABT quarterly cash and cash equivalents has changed by +$849.00 M (+12.65%)